Search

Mecasermin

IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. … The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.

Plasminogen

[L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia). … [A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury.

Glibornuride

Glibornuride is a sulfonylurea-type anti-diabetic drug.

Distearyldimonium

Equine Botulinum Neurotoxin B Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients. … Equine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B.

Testolactone

An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.

Ospemifene

Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause … FDA approved on February 26, 2013.

Berahyaluronidase alfa

It is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

Human cord blood hematopoietic progenitor cell

After the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings. … mismatch due to expanded donor pool, which increases the chance of finding a suitable donor, particularly in patients requiring urgent transplantation [A32219].

Enasidenib

gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. … This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation.